Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Gastric Carcinoma Clinical Trial

Official title:

Albumin-bound Paclitaxel Combined With Toripalimab as First-line/Second-line Treatment of Local Advanced or Metastatic Gastric or Gastroesophageal Junction Carcinoma: A Prospective, Open-label, Single-arm Phase II Clinical Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04443036
• Other study ID #: GC-ATJogress
• Status: Recruiting
• Phase: N/A
• Start date: June 11, 2020
• Est. completion date: December 30, 2023

Study information

• Verified date: June 2020
• Source: China Medical University, China
• Contact: Yunpeng Liu, PhD.
• Phone: 86-24-83282312
• Email: cmuliuyunpeng[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to evaluate the efficacy and safety of Albumin-bound paclitaxel combined with Toripalimab as first-line/second-line treatment of local advanced or metastatic gastric or gastroesophageal junction carcinoma.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 44
• Est. completion date: December 30, 2023
• Est. primary completion date: December 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age:18-70 years old, female or male.

• Histopathologically diagnosed local advanced or metastatic gastric or gastroesophageal junction carcinoma, HER2 negative.

• At least one measurable lesion according to RECIST 1.1.

• =1 prior line. adjuvant/neoadjuvant therapy is allowed, adjuvant/neoadjuvant therapy is considered as the first-line treatment for advanced diseases, if recurrence occurs during the treatment or within 6 months after the last treatment. prior chemotherapy combined with targeted therapy is allowed.

• ECOG performance status of 0 or 1.

• Adequate organ and bone marrow function: ANC=1.5×109/L, PLT=90×109/L, HGB=90g/L,TBil=1.5ULN, ALT=2.5ULN, AST=2.5ULN, Serum Cr=1ULN, endogenous creatinine clearance>60ml/min (Cockcroft-Gault formula).

• The international normalized ratio (INR) = 1.5 and some prothrombin time (PPT or APTT) = 1.5ULN within 7 days before enrollment.

• Expected survival=3 months.

• Signed informed consent (ICF) before enrollment.

• Women of childbearing age must undergo a pregnancy test within 7 days prior to enrollment and have a negative result and are willing to use effective and reliable contraceptive methods during and 6 months after the last treatment.

Exclusion Criteria:

• History of severe allergic reactions to chimeric or humanized antibodies or fusion proteins, or known allergic to any component of Toripalimab or any component of Albumin Bound paclitaxel.

• severe hypersensitivity after previous administration of monoclonal antibody.

• =1 prior line therapy after progression.

• Prior therapy with PD-1?PD-L1/L2?CTLA-4 antibody, or any other immunotherapy.

• A history of organ transplantation.

• Any other malignancy within 5 years excluding healed Basal cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of cervical or breast.

• Received anti-tumor vaccine or other immune-stimulating agents (interferon, interleukin, thymosin, immuno cell therapy, etc.) within 1 month before the first treatment.

• Symptomatic central nervous system metastases.

• Acute or chronic Active hepatitis B or hepatitis C.

• Interstitial pneumonia, pneumoconiosis, drug-induced pneumonia, pulmonary fibrosis, severely impaired lung function and other pulmonary diseases.

• Active tuberculosis, receiving anti-TB treatment or have received anti-TB treatment within 1 year prior to first treatment.

• Human immunodeficiency virus (HIV) infection(HIV antibody positive), or known syphilis infection.

• Severe uncontrolled disease, non-metastatic systemic disease, active or poor clinical control infection.

• Patients with autoimmune diseases or abnormal immune system.

• Treatment with immunosuppressive medications within 4 weeks prior to enrollment. Nasal spray, inhalation, or other ways of topical corticosteroids or systemic corticosteroids at physiologic doses (not to exceed 10 mg/day of prednisone or its equivalent Steroids)are not included.

• Expected to require any other form of antitumor therapy while on study (including maintenance therapy with any other drugs for gastric or gastroesophageal junction carcinoma?radiotherapy and/or surgical resection)

• Received major surgery or radiation therapy of > 30 Gy not to chest within 4 weeks of the first treatment, or radiation therapy of > 30 Gy to chest within 24 weeks of the first treatment,or radiation therapy of < 30 Gy to chest within 2 weeks of the first treatment, and had not recovered from the toxicity and/or complications of the most recent prior chemotherapy to Grade 1 or less (except alopecia or fatigue).

• Poorly Controlled Diabetes(fasting blood-glucose =CTCAE grade 2).

• Clinically significant thyroid dysfunction and can't maintain thyroid hormone levels in the normal range with drugs.

• Use of any live vaccines within 4 weeks before enrollment.

• Pregnant or lactating subjects.

• Participated in any other drug clinical study within 4 weeks before the enrollment.

• Any other disease?metabolic disorders?Physical examination or laboratory abnormalities that might result in contraindications in the use of experimental drugs or affect the reliability of the study, or Puts patients at high risk.

• The investigator believes are not suitable for participating in the study.

Related Conditions & MeSH terms

• Carcinoma
• Gastric Carcinoma
• Stomach Neoplasms

Intervention

Drug:
• Albumin-Bound Paclitaxel
125mg/m2 IV d1?8,Q3W until disease progression, lost follow-up visit, death , unacceptable toxicity
• Toripalimab
240 mg,IV d1,Q3W until disease progression, lost follow-up visit, death , unacceptable toxicity, Maximum treatment duration is 24 months

Locations

Country	Name	City	State
China	The First Hospital of China Medical University	Shenyang	Liaoning

Sponsors (1)

Lead Sponsor	Collaborator
China Medical University, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	Progression-Free Survival; Defined as the time from first dose of study medication to the first documented disease progression per RECIST version 1.1,or death from any cause, whichever occurred first	up to 24 months
Secondary	ORR	Objective Response Rate; Defined as the proportion of patients with confirmed complete response /partial response per RECIST version 1.1	up to 24 months
Secondary	DCR	Disease control rate; Defined as the proportion of patients with confirmed complete response /partial response/ Stable Disease per RECIST version 1.1	up to 24 months
Secondary	OS	Over survival; Defined as the time from the date of first dose of study medication to the date of death from any cause	up to 24 months
Secondary	Change in Quality of Life(QoL):measured by EORTC QLQ-C30 questionnaire	European Organisation for Research and Treatment of Cancer's Quality of Life Questionnaire Core 30 (EORTC QLQ-C30); The change in the quality of life as measured by EORTC QLQ-C30, consists of 30 questions that provide a global QoL scale, five functional scales (physical, role-playing, emotional, cognitive, social), three symptom scales (fatigue, nausea and vomiting, pain) and six individual factors (dyspnea, insomnia, loss of appetite, constipation, diarrhea, financial difficulties). The scores of each scale are calculated in a score ranging from 0 to 100. A high score on a functional scale represents a good level of function.	up to 24 months
Secondary	Adverse events	- Defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0	up to 24 months